Adam Bass

Publications (5)92.07 Total impact

• Article: Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.

  Adam Bass
  Journal of Clinical Oncology 06/2011; 29(19):2728-9. · 18.37 Impact Factor
• Article: Amplification of chromosomal segment 4q12 in non-small cell lung cancer.

  Alex H Ramos, Amit Dutt, Craig Mermel, Sven Perner, Jeonghee Cho, Christopher J Lafargue, Laura A Johnson, Ann-Cathrin Stiedl, Kumiko E Tanaka, Adam J Bass, [......], Roman K Thomas, John D Minna, Lucian R Chirieac, Neal I Lindeman, Thomas Giordano, David G Beer, Patrick Wagner, Ignacio I Wistuba, Mark A Rubin, Matthew Meyerson
  [show abstract] [hide abstract]
  ABSTRACT: In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFRalpha activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFRalpha/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors.
  Cancer biology & therapy 11/2009; 8(21):2042-50. · 2.64 Impact Factor
• Article: The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

  Mark M Pomerantz, Nasim Ahmadiyeh, Li Jia, Paula Herman, Michael P Verzi, Harshavardhan Doddapaneni, Christine A Beckwith, Jennifer A Chan, Adam Hills, Matt Davis, [......], Baruch Frenkel, Jordi Barretina, Adam Bass, Josep Tabernero, José Baselga, Meredith M Regan, J Robert Manak, Ramesh Shivdasani, Gerhard A Coetzee, Matthew L Freedman
  [show abstract] [hide abstract]
  ABSTRACT: An inherited variant on chromosome 8q24, rs6983267, is significantly associated with cancer pathogenesis. We present evidence that the region harboring this variant is a transcriptional enhancer, that the alleles of rs6983267 differentially bind transcription factor 7-like 2 (TCF7L2) and that the risk region physically interacts with the MYC proto-oncogene. These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant.
  Nature Genetics 07/2009; 41(8):882-4. · 35.53 Impact Factor
• Article: A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

  Outi Kilpivaara, Semanti Mukherjee, Alison M Schram, Martha Wadleigh, Ann Mullally, Benjamin L Ebert, Adam Bass, Sachie Marubayashi, Adriana Heguy, Guillermo Garcia-Manero, Hagop Kantarjian, Kenneth Offit, Richard M Stone, D Gary Gilliland, Robert J Klein, Ross L Levine
  [show abstract] [hide abstract]
  ABSTRACT: Polycythemia vera, essential thrombocythemia and primary myelofibrosis are myeloproliferative neoplasms (MPN) characterized by multilineage clonal hematopoiesis. Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders. Moreover, family members of individuals with MPN are at higher risk for the development of MPN, consistent with the existence of MPN predisposition loci. We hypothesized that germline variation contributes to MPN predisposition and phenotypic pleiotropy. Genome-wide analysis identified an allele in the JAK2 locus (rs10974944) that predisposes to the development of JAK2(V617F)-positive MPN, as well as three previously unknown MPN modifier loci. We found that JAK2(V617F) is preferentially acquired in cis with the predisposition allele. These data suggest that germline variation is an important contributor to MPN phenotype and predisposition.
  Nature Genetics 05/2009; 41(4):455-9. · 35.53 Impact Factor
• Article: A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

  Outi Kilpivaara, Semanti Mukherjee, Alison M Schram, Martha Wadleigh, Ann Mullally, Benjamin L Ebert, Adam Bass, Sachie Marubayashi, Adriana Heguy, Guillermo Garcia-Manero, Hagop Kantarjian, Kenneth Offit, Richard M Stone, D Gary Gilliland, Robert J Klein, Ross L Levine